Clinical Research Directory

Inclusion Criteria: * Patients with a physician-reported diagnosis of moderate-to-severe plaque psoriasis initiating deucravacitinib according to approved label in the European Union * The decision upon treatment with deucravacitinib must have been made before enrollment and independently of this non-interventional observational study * Patient is at least 18 years of age at the time of treatment decision * Patient provided written informed consent to participate in the study Exclusion Criteria: * Any contraindications according to the approved deucravacitinib Summary of Product Characteristics * Prior treatment with deucravacitinib * Simultaneous participation in an interventional clinical trial for moderate-to-severe psoriasis